Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nivolumab + docetaxel + cisplatin followed by surgery and radiotherapy for resectable high-grade salivary gland carcinoma
KCT0007702Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, docetaxel, cisplatin in salivary gland cancer (SGC), sponsored by Ono Pharmaceutical. Started Nov 2022; status: active, not recruiting.
02
Drugs
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on KCT0007702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007702.